BioWorld

Dec. 2, 2009

Protalix: $115M Gaucher's Deal with Pfizer is Just the Beginning

Shares of Protalix BioTherapeutics Inc. dipped 13.7 percent on Tuesday after the biotech unveiled a $115 million profit-sharing deal with Pfizer Inc. for Gaucher's disease drug Uplyso (taliglucerase alfa). (BioWorld Today) Read More

Synagis, Synergy: Trellis Getting $338M In RSV MedImmune Deal

Forma Moving from Platform to Pipeline with $25M Series B

NewCo News: Syntiron Dressing Up Turkey Vaccine; Possible Human Use

Bayer Schering Bites on BiTE Option for Micromet Antibody

Other News To Note

Clinic Roundup

Bio Korea 2026 kicks off with spotlight on oligonucleotides

BioWorld

Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...

University of Western Australia patents 5-HT2A/B modulators

BioWorld Science

University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...

AA meeting of minds as PTC, Novartis push votoplam in HD

BioWorld

What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...

Innervation can slow, as well as speed, tumor growth, study finds

BioWorld

Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...

Alceptor Therapeutics discovers new α2B-adrenoceptor agonists

BioWorld Science

Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.